Safety and Efficacy of Ropeginterferon Alfa-2b in Combination With Ruxolitinib in Patients With Myelofibrosis Demonstrating Suboptimal Response to Ruxolitinib Monotherapy
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Ropeginterferon alfa-2b (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- 20 Jan 2025 New trial record